226400.Kq
The company operates in the healthcare services and equipment industry, primarily generating revenue through the provision of medical equipment, supplies, and distribution services.
Business. The company operates in the healthcare services and equipment industry, primarily generating revenue through the provision of medical equipment, supplies, and distribution services.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare services and equipment industry, primarily generating revenue through the provision of medical equipment, supplies, and distribution services.
The company maintains a strong liquidity position, with a current ratio of 2.96, indicating a robust ability to meet short-term obligations. Its price-to-book ratio of 1.68 and price-to-tangible-book ratio of 1.68 suggest that the market values the company's equity at a premium relative to its book value. The company's return on equity of 11.12% and return on assets of 7.47% indicate that it is generating solid returns for shareholders and effectively utilizing its assets.
The company's profitability is reflected in its operating income of 9,774,629,150 KRW and net income of 7,498,732,160 KRW, which are in line with the industry's preferred metrics for profitability. The gross profit of 22,067,385,770 KRW and operating margin of 21.54% (calculated from operating income and revenue) suggest that the company is efficiently managing its production and operational costs.
The company's revenue is concentrated in a single segment, as disclosed in the financial snapshot, with no specific geographic breakdown provided. This lack of geographic diversification may expose the company to regional economic fluctuations and regulatory changes.
The company's growth trajectory is positive, with a revenue of 45,393,099,440 KRW and a free cash flow of 2,243,259,180 KRW, indicating that it is generating sufficient cash to support operations and potential expansion. The capital expenditure of -8,950,777,870 KRW suggests that the company is investing in its long-term growth.
The company's risk assessment indicates a medium liquidity risk and a low dilution risk, with key flags noting that net cash is negative after subtracting total debt. The dilution potential is low, and no adjustments have been applied to the valuation metrics.
Recent events, as reflected in the financial data, show that the company has a strong analyst following, with a mean price target of 13,000.00 KRW and a mean recommendation of 1.00, indicating a strong buy consensus. No specific filings or transcripts have been provided to detail recent corporate actions or strategic developments.
- The company has a strong liquidity position with a current ratio of 2.96.
- The company's return on equity of 11.12% and return on assets of 7.47% indicate solid profitability.
- The company's revenue is concentrated in a single segment, which may pose a risk to its growth and stability.
- The company's free cash flow of 2,243,259,180 KRW supports its operations and potential expansion.
- The company has a low dilution risk and a medium liquidity risk.
- Analysts have a strong buy consensus with a mean price target of 13,000.00 KRW.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 529,00 |
| Revenue | —no estimate | —no estimate | 55,0B KRW |
| Operating income | —no estimate | —no estimate | 14,0B KRW |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- 226400.KQ Market data — financials · 2026-05-26
- Osteonic Co Ltd Market data — analyst estimates · 2026-05-26